Citi Says Moderna Looks Too Expensive After Cancer-Vaccine Rally
Citi says Moderna’s rally after the INTerpath-001 melanoma win pushed its market value near Regeneron’s despite weaker near-term earnings.
/ 32 items
#MRNA↓
Moderna Plans a $2 Billion Convertible-Note Sale After Last Week’s Cancer-Vaccine Rally
Moderna intends to sell $2B of zero-coupon notes due 2032, plus a $300M option, after a melanoma vaccine rally. Shares slipped on dilution risk.
Wolfe Research Upgrades Moderna to Peer Perform After Cancer Vaccine Breakthrough
Wolfe Research upgrades Moderna to Peer Perform following Phase 3 intismeran success and a potential $9.2 billion peak sales outlook.
Arbutus Biopharma Plans $230 Million Share Buyback After Moderna Patent Win
Arbutus Biopharma will repurchase up to $230M in shares via Dutch auction, funded by its $950M Moderna LNP patent settlement. Offer range $5–$5.75.
From Moderna to Sellas: The Next Major Catalyst in Cancer Vaccines
Sellas GPS data is imminent, Maxim keeps Buy/$30 PT. BNTX also in focus.
Wells Fargo and Stifel Flag Beneficiaries of Moderna-Merck Cancer Vaccine Data
Wells Fargo and Stifel say Moderna and Merck's Phase 3 cancer vaccine data could benefit Repligen, Danaher, Thermo Fisher, and Maravai LifeSciences. TEM stock is also surging.